View Future GrowthStemtech 과거 순이익 실적과거 기준 점검 0/6Stemtech은 연평균 9.6%의 비율로 수입이 증가해 온 반면, Personal Products 산업은 연평균 1.1%의 비율로 감소했습니다. 매출은 연평균 2.3%의 비율로 증가했습니다.핵심 정보9.59%순이익 성장률36.75%주당순이익(EPS) 성장률Personal Products 산업 성장률20.87%매출 성장률2.25%자기자본이익률n/a순이익률-79.34%최근 순이익 업데이트30 Sep 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2026, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Jan 07Stemtech Corporation Appoints Dr. Lizette Leos, MD as Chief Scientific OfficerStemtech Corporation appointed Dr. Lizette Leos, MD to Chief Scientific Officer. Dr. Leos has been with Stemtech since 2017 and has significantly contributed to the science, creation and development, including education of stemceuticals all-natural, plant-based, non-GMO nutritional supplements designed to support the body's own regenerative processes. Promoting her to the role of Chief Scientific Officer recognizes both her longstanding impact and leadership in the development of new evidence-driven innovations. Her scientific knowledge of products, ability to translate complex biology into practical education, and commitment to Stemtech's non-chemical approaches to cellular health have been instrumental to Stemtech's growth, with focus on anti-aging and longevity. As Chief Scientific Officer, Dr. Leos will lead Stemtech Corporation's global scientific validation, education and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd. and the GCC (Gulf Cooperation Council countries of the United Arab Emirates, Bahrain, Saudi Arabia, Qatar, Kuwait and Oman). In addition, Dr. Leos will also support Stemtech Asia (Hong Kong) for business in the Peoples Republic of China. Dr. Leos is a medical doctor based in Guadalajara, Mexico, and has worked with Stemtech since 2017. She holds a Master's Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica (IMMAE) (2023), postgraduate training in Molecular Nutrition and Smart Food Design from Tecnológico de Monterrey, Campus Guadalajara (2018), and earned her Medical Degree from Universidad Guadalajara Lamar, with her professional title issued by the Universidad de Guadalajara (2007). With over 10 years of experience in regenerative medicine, nutrigenomics, cellular health, and aesthetic medicine, Dr. Leos has served on the Stemtech Life Sciences Advisory Board, where she has designed global educational programs, scientific symposiums, and evidence-based clinical and educational protocols. She brings deep expertise in scientific and medical communication, clinical protocol development, and cross-functional collaboration across scientific, regulatory, and commercial teams. Fluent in English and Spanish, she contributes significant cross-cultural leadership to Stemtech's international operations.공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • May 16+ 1 more updateStemtech Corporation announced delayed amended 10-Q filingOn 05/15/2025, Stemtech Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.공지 • Apr 15Stemtech Corporation Announces CFO ChangesOn April 11, 2025, James Cardwell resigned his position as CFO of Stemtech Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005.공지 • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2025, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Dec 02Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction.Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. The proposal suggests that Eevia buy the Stemtech's assets (“Stemtech Assets”) and issue new shares to the Stemtech, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech's valuation would be approximately $40 million, and the remaining 15% of the shares would value Eevia at approximately $6-7 million. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies.공지 • Nov 20Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC.Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC on November 20, 2024. The proposed merger is expected to be for all stock consideration and is subject to conditions to closing, including required board and shareholder approvals, the finalization of definitive agreements, the audit of VIÁGO financial statements and other customary conditions. Stemtech and VIÁGO expect to finalize the definitive agreements for the merger soon.공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Aug 23Stemtech Corporation Announces the Launch of StemPetsStemtech Corporation announced an exciting new product line into the pet health care industry with the launch of StemPets™?. This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market. Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as human products have provided for nearly two decades. Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through established channels. Over the past year, company has tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits. This expansion into the pet health care industry also presents a significant opportunity for younger distributors of products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in mission to improve lives, both human and animal.공지 • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • May 17Stemtech Corporation announced delayed 10-Q filingOn 05/15/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Mar 30Stemtech Corporation announced delayed annual 10-K filingOn 03/29/2024, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2023, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Jan 11Stemtech Corporation Appoints Margie and Mike Mares to Field Advisory BoardStemtech Corporation announced the appointment of Margie and Mike Mares of Stemtech Mexico to Stemtech's Field Advisory Board (FAB). Margie has a degree in Communications and has also worked in the cosmetic industry as a senior executive in the areas of sales, marketing and public relations. Mike has earned a Bachelor of Business Administration and Marketing from UP and a Professional Photographer from NYIP. He has experience in marketing, e-commerce, Community Management and growth of markets and social networks, management and the creation of bots, logistics and finance.공지 • Dec 07Stemtech Corporation Announces Introduction of Cellectone Rapid Renew Stem Cell Peptide Night CreamStemtech Corporation (Stemtech) announced the introduction of their new CellectOne™ innovative and cutting-edge Skincare line, with the first product being the Rapid Renew Stem Cell Peptide Night Cream.공지 • Sep 20Stemtech Corporation Announces Creation of New Stem Cell Skincare ProductsStemtech Corporation announced creation of new stem cell skincare products.공지 • Sep 07Stemtech Corporation Announces Professor Dr. Bankole Johnson Joins Their Life Sciences Advisory BoardStemtech Corporation announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Forbes Magazine articulated that “Dr. Johnson was a fully-practicing MD by the age of 22, when he became an intensive care doctor. After that, and after completing the necessary schooling, he became an anesthesiologist, and then a psychiatrist. He further pursued higher education with the completion of two more doctorates in addition to his MD, and a Masters Degree in neurological disorders and computational mathematics. While practicing medicine and making discoveries in the areas of psychopharmacology in the treatment of addiction, he rose in academia to become the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, followed by a similar role at the University of Maryland where he was Chairman of Psychiatry and Professor of pharmacology, medicine, psychiatry, anatomy, neurobiology, and neurology.” Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic. Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.공지 • Aug 30Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research.Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022.공지 • Aug 24Stemtech Corporation Announces Orastem Trademark Registration in Mexico and Introduces New Travel SizeStemtech Corporation announced that OraStem®, Stemtech’s all-natural toothpaste, has been trademarked registered in Mexico. OraStem is composed of fourteen natural, non-GMO, and organic ingredients: powerful antioxidants, botanicals, herbal extracts, CoQ10, vitamins, and natural flavors. Their efficacy and safety for oral health have been supported by dozens of studies published in peer-reviewed journals. Stemtech will also be introducing a new sample /travel size of OraStem soon. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from the bone marrow. Also offered is the OraStem and D-Fuze, an Electro Magnetic Field blocker. Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation and was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs.매출 및 비용 세부 내역Stemtech가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:STEK 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 254-35030 Jun 254-35031 Mar 255-46031 Dec 245-46030 Sep 245-58030 Jun 245-58031 Mar 245-58031 Dec 235-58030 Sep 235-47030 Jun 234149031 Mar 235-109031 Dec 225-98030 Sep 225-910030 Jun 225-327031 Mar 224-77031 Dec 214-77030 Sep 214-76030 Jun 214-24031 Mar 214-14031 Dec 204-15031 Dec 197-380양질의 수익: STEK 은(는) 현재 수익성이 없습니다.이익 마진 증가: STEK는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: STEK는 수익성이 없지만 지난 5년 동안 연평균 9.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 STEK의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: STEK은 수익성이 없어 지난 해 수익 성장률을 Personal Products 업계(-8.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: STEK의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHousehold 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/11 15:44종가2026/05/11 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Stemtech Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공지 • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2026, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Jan 07Stemtech Corporation Appoints Dr. Lizette Leos, MD as Chief Scientific OfficerStemtech Corporation appointed Dr. Lizette Leos, MD to Chief Scientific Officer. Dr. Leos has been with Stemtech since 2017 and has significantly contributed to the science, creation and development, including education of stemceuticals all-natural, plant-based, non-GMO nutritional supplements designed to support the body's own regenerative processes. Promoting her to the role of Chief Scientific Officer recognizes both her longstanding impact and leadership in the development of new evidence-driven innovations. Her scientific knowledge of products, ability to translate complex biology into practical education, and commitment to Stemtech's non-chemical approaches to cellular health have been instrumental to Stemtech's growth, with focus on anti-aging and longevity. As Chief Scientific Officer, Dr. Leos will lead Stemtech Corporation's global scientific validation, education and regulatory alignment for Stemtech's recently announced joint ventures in Stemtech HealthSciences India Pvt Ltd. and the GCC (Gulf Cooperation Council countries of the United Arab Emirates, Bahrain, Saudi Arabia, Qatar, Kuwait and Oman). In addition, Dr. Leos will also support Stemtech Asia (Hong Kong) for business in the Peoples Republic of China. Dr. Leos is a medical doctor based in Guadalajara, Mexico, and has worked with Stemtech since 2017. She holds a Master's Degree in Aesthetic and Anti-Aging Medicine from the Instituto Mexicano de Medicina Antienvejecimiento y Esttica (IMMAE) (2023), postgraduate training in Molecular Nutrition and Smart Food Design from Tecnológico de Monterrey, Campus Guadalajara (2018), and earned her Medical Degree from Universidad Guadalajara Lamar, with her professional title issued by the Universidad de Guadalajara (2007). With over 10 years of experience in regenerative medicine, nutrigenomics, cellular health, and aesthetic medicine, Dr. Leos has served on the Stemtech Life Sciences Advisory Board, where she has designed global educational programs, scientific symposiums, and evidence-based clinical and educational protocols. She brings deep expertise in scientific and medical communication, clinical protocol development, and cross-functional collaboration across scientific, regulatory, and commercial teams. Fluent in English and Spanish, she contributes significant cross-cultural leadership to Stemtech's international operations.
공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2025, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • May 16+ 1 more updateStemtech Corporation announced delayed amended 10-Q filingOn 05/15/2025, Stemtech Corporation announced that they will be unable to file their amended 10-Q by the deadline required by the SEC.
공지 • Apr 15Stemtech Corporation Announces CFO ChangesOn April 11, 2025, James Cardwell resigned his position as CFO of Stemtech Corporation. At the same time the Board appointed Shrilakshmi Vadlapatla as CFO. Ms. Vadlapatla, 40, is a seasoned boutique accountant with years of experience in audit compliance, SEC reporting, internal controls, Sarbanes-Oxley compliance and strategic financial management. With a strong background in GAAP and IFRS principles, earnings analysis, and external audits, she provides expertise in risk assessment, Sarbanes-Oxley compliance, and the development of robust financial policies and procedures. Ms. Vadlapatla holds a Bachelor of Commerce in Accounting from Osmania University, (India), 2005.
공지 • Apr 01Stemtech Corporation announced delayed annual 10-K filingOn 03/31/2025, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Dec 02Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction.Stemtech Corporation signed a letter of intent to acquire Eevia Health Oyj (NGM:EEVIA) in a reverse merger transaction on November 10, 2024. The proposal suggests that Eevia buy the Stemtech's assets (“Stemtech Assets”) and issue new shares to the Stemtech, providing that Stemtech will own c. 85% of the new outstanding shares after such a transaction. Stemtech's valuation would be approximately $40 million, and the remaining 15% of the shares would value Eevia at approximately $6-7 million. The final valuation, number of shares to be issued, and issue price are subject to negotiation and the due diligence process of both companies.
공지 • Nov 20Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC.Stemtech Corporation (OTCPK:STEK) entered into an agreement in principle to acquire SEACRET Direct, LLC on November 20, 2024. The proposed merger is expected to be for all stock consideration and is subject to conditions to closing, including required board and shareholder approvals, the finalization of definitive agreements, the audit of VIÁGO financial statements and other customary conditions. Stemtech and VIÁGO expect to finalize the definitive agreements for the merger soon.
공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Aug 23Stemtech Corporation Announces the Launch of StemPetsStemtech Corporation announced an exciting new product line into the pet health care industry with the launch of StemPets™?. This revolutionary product is designed to provide substantial health benefits to dogs, cats, and other beloved pets, tapping into the $303 billion pet health care market. Recognizing the profound love humans hold for their pets and the significant expenses they incur to keep them healthy, Stemtech has developed StemPets. This natural stemceutical product promises to offer amazing health benefits to pets as human products have provided for nearly two decades. Stemtech has negotiated an exclusive distribution agreement for StemPets, ensuring that this novel product will be available through established channels. Over the past year, company has tested StemPets with a variety of pet owners, receiving overwhelmingly positive feedback regarding its natural taste and health benefits. This expansion into the pet health care industry also presents a significant opportunity for younger distributors of products, including Gen X individuals under 40 who may not yet prioritize human stem cell health but are enthusiastic about superior health products for their pets. Stemtech's dedication to scientific innovation and health continues with the introduction of StemPets, marking a new chapter in mission to improve lives, both human and animal.
공지 • Aug 15Stemtech Corporation announced delayed 10-Q filingOn 08/14/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • May 17Stemtech Corporation announced delayed 10-Q filingOn 05/15/2024, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Mar 30Stemtech Corporation announced delayed annual 10-K filingOn 03/29/2024, Stemtech Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공지 • Nov 15Stemtech Corporation announced delayed 10-Q filingOn 11/14/2023, Stemtech Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Jan 11Stemtech Corporation Appoints Margie and Mike Mares to Field Advisory BoardStemtech Corporation announced the appointment of Margie and Mike Mares of Stemtech Mexico to Stemtech's Field Advisory Board (FAB). Margie has a degree in Communications and has also worked in the cosmetic industry as a senior executive in the areas of sales, marketing and public relations. Mike has earned a Bachelor of Business Administration and Marketing from UP and a Professional Photographer from NYIP. He has experience in marketing, e-commerce, Community Management and growth of markets and social networks, management and the creation of bots, logistics and finance.
공지 • Dec 07Stemtech Corporation Announces Introduction of Cellectone Rapid Renew Stem Cell Peptide Night CreamStemtech Corporation (Stemtech) announced the introduction of their new CellectOne™ innovative and cutting-edge Skincare line, with the first product being the Rapid Renew Stem Cell Peptide Night Cream.
공지 • Sep 20Stemtech Corporation Announces Creation of New Stem Cell Skincare ProductsStemtech Corporation announced creation of new stem cell skincare products.
공지 • Sep 07Stemtech Corporation Announces Professor Dr. Bankole Johnson Joins Their Life Sciences Advisory BoardStemtech Corporation announced that Professor Dr. Bankole Johnson joins the Stemtech Corporation Life Sciences Advisory Board (LSAB). Forbes Magazine articulated that “Dr. Johnson was a fully-practicing MD by the age of 22, when he became an intensive care doctor. After that, and after completing the necessary schooling, he became an anesthesiologist, and then a psychiatrist. He further pursued higher education with the completion of two more doctorates in addition to his MD, and a Masters Degree in neurological disorders and computational mathematics. While practicing medicine and making discoveries in the areas of psychopharmacology in the treatment of addiction, he rose in academia to become the Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia, followed by a similar role at the University of Maryland where he was Chairman of Psychiatry and Professor of pharmacology, medicine, psychiatry, anatomy, neurobiology, and neurology.” Professor Dr. Bankole Johnson gained national attention for his appearance in the Home Box Office (HBO) 2007 documentary Addiction, which won the Governor’s Award (a special Emmy Award) from the Academy of Television Arts and Sciences. This being the highest award presented by the Academy. He also appeared on the esteemed 2009 CNN special, anchored by Chief Medical Correspondent Dr. Sanjay Gupta, called Addiction: Life on the Edge. Furthermore, Professor Dr. Bankole Johnson is a regular medical correspondent for major network channels in the USA, especially during the COVID-19 pandemic. Presently, Dr. Johnson is the Founder, Executive Chairman, and CEO of Casa Privée, based in Miami, and the Founder and Chief Medical Officer of Adial Pharmaceuticals Inc., a NASDAQ listed company. Professor Dr. Johnson also functions as a Professor of Biomedical Sciences at Larkin University in Miami.
공지 • Aug 30Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research.Stemtech Corporation (OTCPK:STEK) entered into a letter of intent to acquire Life Factor Research on August 29, 2022.
공지 • Aug 24Stemtech Corporation Announces Orastem Trademark Registration in Mexico and Introduces New Travel SizeStemtech Corporation announced that OraStem®, Stemtech’s all-natural toothpaste, has been trademarked registered in Mexico. OraStem is composed of fourteen natural, non-GMO, and organic ingredients: powerful antioxidants, botanicals, herbal extracts, CoQ10, vitamins, and natural flavors. Their efficacy and safety for oral health have been supported by dozens of studies published in peer-reviewed journals. Stemtech will also be introducing a new sample /travel size of OraStem soon. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the body’s adult stem cells from the bone marrow. Also offered is the OraStem and D-Fuze, an Electro Magnetic Field blocker. Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation and was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtech’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs.